5-(3-bromobenzylidene)-2-thioxothiazolidin-4-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3-bromobenzylidene)-2-thioxothiazolidin-4-one
• 英文别名: (5Z)-5-[(3-bromophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one；5-[(3-bromophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
• 化学式: C₁₀H₆BrNOS₂
• 分子量: 300.2
• InChiKey: OTYMLMRHOPDJMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(3-bromobenzylidene)-2-thioxothiazolidin-4-one 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors

  摘要：

  A type of novel rhodanine-based 4-anilinoquinazoline, which designed the combination between quinazoline as the backbone and various substituted biological rhodanine groups as the side chain, have been synthesized, and their antiproliferative activities were also evaluated firstly. These compounds displayed good antiproliferative activity and EGFR-TK inhibitory activity. Among them, compound 8d showed good inhibitory activity (IC50 = 2.7 mu M for Hep G2, IC50 = 3.1 mu M for A549) and molecular docking of 8d into EGFR TK active site was also performed, this inhibitor well fitting the active site might well explain its excellent inhibitory activity. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.04.065
• 作为产物：
  描述：

  罗丹宁 、 间溴苯甲醛 在 sodium acetate 、 溶剂黄146 作用下， 以70%的产率得到5-(3-bromobenzylidene)-2-thioxothiazolidin-4-one
  参考文献：
  名称：

  新型美格列奈的合成、分子建模、选择性醛糖还原酶抑制和降血糖活性

  摘要：

  在本研究中，设计并调节了具有显着降血糖活性的新一代选择性醛糖还原酶 ALR2 抑制剂，其基础是在两个亲脂性部分之间连接到乙酰胺接头的罗丹宁支架。新化合物的合成是通过简单的化学途径完成的。在B细胞膜蛋白 SUR1、醛还原酶 ALR1 和醛糖还原酶 ALR2 活性位点上进行分子对接。化合物10B、11B、12B、15C、16C、26F和27F显示出最高的降血糖活性，血糖水平分别降低了 80.7、85.2、87、82.3、83.5、81.4 和 85.3%。它们比标准降血糖药瑞格列奈更有效，血糖水平降低 65.4%。IC 50 0.29 和 0.35 µM 的化合物12B和15C比 IC 50 0.40 µM的标准 ALR2 抑制剂依帕司他更有效。它们对 ALR2 的选择性分别超过 ALR1 134 和 116 倍。分子对接研究与体外和体内结果相匹配，以阐明化合物12B和15C的双重活性 作为 ALR2

  DOI：

  10.1016/j.bioorg.2021.104909

文献信息

• Synthesis, molecular modeling, selective aldose reductase inhibition and hypoglycemic activity of novel meglitinides
  作者：Manar G. Salem、Yasmine M. Abdel Aziz、Marwa Elewa、Mohamed S. Nafie、Hosam A. Elshihawy、Mohamed M. Said

  DOI：10.1016/j.bioorg.2021.104909

  日期：2021.6

  In the present study, a novel generation of selective aldose reductase ALR2 inhibitors with significant hypoglycemic activities was designed and modulated based on rhodanine scaffold joined to an acetamide linker in between two lipophilic moieties. The synthesis of the novel compounds was accomplished throughout simple chemical pathways. Molecular docking was performed on B-cell membrane protein SUR1

  在本研究中，设计并调节了具有显着降血糖活性的新一代选择性醛糖还原酶 ALR2 抑制剂，其基础是在两个亲脂性部分之间连接到乙酰胺接头的罗丹宁支架。新化合物的合成是通过简单的化学途径完成的。在B细胞膜蛋白 SUR1、醛还原酶 ALR1 和醛糖还原酶 ALR2 活性位点上进行分子对接。化合物10B、11B、12B、15C、16C、26F和27F显示出最高的降血糖活性，血糖水平分别降低了 80.7、85.2、87、82.3、83.5、81.4 和 85.3%。它们比标准降血糖药瑞格列奈更有效，血糖水平降低 65.4%。IC 50 0.29 和 0.35 µM 的化合物12B和15C比 IC 50 0.40 µM的标准 ALR2 抑制剂依帕司他更有效。它们对 ALR2 的选择性分别超过 ALR1 134 和 116 倍。分子对接研究与体外和体内结果相匹配，以阐明化合物12B和15C的双重活性 作为 ALR2
• Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors
  作者：Si-Ning Li、Yun-Yun Xu、Jia-Yu Gao、Hong-ran Yin、Shi-Lei Zhang、Huan-Qiu Li

  DOI：10.1016/j.bmc.2015.04.065

  日期：2015.7

  A type of novel rhodanine-based 4-anilinoquinazoline, which designed the combination between quinazoline as the backbone and various substituted biological rhodanine groups as the side chain, have been synthesized, and their antiproliferative activities were also evaluated firstly. These compounds displayed good antiproliferative activity and EGFR-TK inhibitory activity. Among them, compound 8d showed good inhibitory activity (IC50 = 2.7 mu M for Hep G2, IC50 = 3.1 mu M for A549) and molecular docking of 8d into EGFR TK active site was also performed, this inhibitor well fitting the active site might well explain its excellent inhibitory activity. (C) 2015 Elsevier Ltd. All rights reserved.
• 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors
  作者：Yanghwan Yun、Victor Sukbong Hong、Seungik Jeong、Hyeonseong Choo、Shin Kim、Jinho Lee

  DOI：10.1248/cpb.c21-00264

  日期：2021.9.1

  derivatives were synthesized and evaluated as potent pan-PIM kinase inhibitors. Optimized compounds showed single-digit nanomolar IC50 values against all three PIM kinases with high selectivity over 14 other kinases. Compound 17 inhibited the growth of Molm-16 cell lines (EC50 = 14 nM) and modulated the expression of pBAD and p4EBP1 in a dose-dependent manner. Fullsize Image

  莫洛尼鼠白血病病毒 (PIM) 激酶的原病毒整合位点是参与调节多种细胞过程的原癌激酶。PIM 激酶是新药开发的有希望的靶点，因为它们在许多癌症特异性途径中发挥重要作用，例如存活、细胞凋亡、增殖、细胞周期调节和迁移。在这里，2-thioxothiazolidin-4-one 衍生物被合成并评估为有效的泛 PIM 激酶抑制剂。优化的化合物对所有三种 PIM 激酶均显示出个位数纳摩尔 IC 50值，并且选择性高于其他 14 种激酶。化合物17抑制 Molm-16 细胞系 (EC 50  = 14 nM) 的生长并以剂量依赖性方式调节 pBAD 和 p4EBP1 的表达。 全尺寸图像